Medical experts proposed a radical overhaul of how obesity is diagnosed, moving away from relying on body mass alone and ...

The recommendation signals a long-awaited shift from a single imperfect metric toward a more personalised diagnosis ...

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geoff Meacham ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...

The pharmaceutical industry is poised for a dynamic year in 2025. A confluence of positive trends suggests a brighter outlook ...

Older studies estimated a lower risk of dementia. According to new research, the number of people living with the disease in ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...